Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
LEQEMBI®, a new at-home Alzheimer’s drug, named a 2025 TIME Best Invention, treats early stages of the disease with a quick self-injection.
LEQEMBI® IQLIK™ (lecanemab-irmb), a subcutaneous autoinjector for early Alzheimer’s disease, has been named a 2025 TIME Best Invention in medical and healthcare.
Developed by Eisai and Biogen, it’s the first anti-amyloid therapy approved for at-home use, allowing patients with mild cognitive impairment or mild dementia to self-administer treatment after an initial clinic phase.
Approved in the U.S. in August 2025 and launched October 6, it delivers a dose in about 15 seconds, reducing need for IV infusions and easing healthcare system strain.
The drug is approved in 50 countries, with more reviews pending.
It carries a warning for amyloid-related imaging abnormalities (ARIA), which can be serious or fatal, particularly in ApoE ε4 carriers.
Testing for the gene is advised but not required.
LEQEMBI®, un nuevo medicamento para el Alzheimer en el hogar, nombrado mejor invento de 2025 por TIME, trata las primeras etapas de la enfermedad con una rápida autoinyección.